SBBP - ストロングブリッジ・バイオファ―マ (Strongbridge Biopharma plc) ストロングブリッジ・バイオファ―マ

 SBBPのチャート


 SBBPの企業情報

symbol SBBP
会社名 Strongbridge Biopharma plc (ストロングブリッジ・バイオファ―マ)
分野(sector) Health Care   ヘルスケア
産業(industry) Major Pharmaceuticals  
業種 医薬品   医療関連(Health Care)
概要 事業概要 ストロングブリッジ・バイオファーマー(Strongbridge Biopharma plc)はグローバル商業段階のバイオ医薬品会社である。同社は各種疾患の治療法の開発・商品化に従事する。商業製品のKEVEYIS(ジクロロフェナミド)は原発性周期性麻痺の高カリウム血症、低カリウム血症および関連変種の治療に応用される。米国食品医薬品局(FDA)はKEVEYISの希少疾病用医薬品指定を認可している。同社は内分泌疾患治療用の臨床段階パイプラインを保有する。同社のリード化合物には、COR-003(レボケトコナゾール)、コルチゾール合成阻害剤、およびCOR-005(ベルドレイド)、ソマトスタチン類似体(SSA)が含まれる。同社は内在性クッシング症候群の治療のためにCOR-003を研究し、先端巨大症の治療のためにCOR-005を研究している。COR-003とCOR-005の両方は、FDAおよび欧州医薬品庁(EMA)から希少疾病用医薬品指定を受ける。   ストロングブリッジ・バイオファ―マはアイルランドのバイオ医薬品企業。主に稀有な疾患に焦点を当て、複数の相補型薬剤の開発とライセンス化に従事する。革新的な治療が求められる内分泌疾患の内因性クッシング症候群と先端巨大症に対する治療薬「COR-003」を、開発段階の薬剤候補に含む。本社はダブリン。米国ペンシルベニア州にも本社機能を持つ。   Strongbridge Biopharma is a global commercial-stage biopharmaceutical company focused on the development and commercialization of therapies for rare diseases with significant unmet needs. Strongbridge's rare endocrine franchise includes RECORLEV® (levoketoconazole), a cortisol synthesis inhibitor currently being studied in Phase 3 clinical studies for the treatment of endogenous Cushing's syndrome, and veldoreotide extended release, a preclinical next-generation somatostatin analog being investigated for the treatment of acromegaly and potential additional applications in other conditions amenable to somatostatin receptor activation. Both RECORLEV and veldoreotide have received orphan drug designation from the FDA and the European Medicines Agency. The Company's rare neuromuscular franchise includes KEVEYIS® (dichlorphenamide), the first and only FDA-approved treatment for hyperkalemic, hypokalemic, and related variants of primary periodic paralysis. KEVEYIS has orphan drug exclusivity in the United States.
本社所在地 900 Northbrook Drive Suite 200 Trevose PA 19053 USA
代表者氏名 John H. Johnson ジョンH.ジョンソン
代表者役職名 Chairman of the Board 取締役会会長
電話番号 +1 610-254-9200
設立年月日 42125
市場名 NASDAQ National Market System
ipoyear 2015年
従業員数 66人
url www.strongbridgebio.com
nasdaq_url https://www.nasdaq.com/symbol/sbbp
adr_tso
EBITDA EBITDA(百万ドル) -55.10100
終値(lastsale) 4.89
時価総額(marketcap) 228412134.72
時価総額 時価総額(百万ドル) 233.55020
売上高 売上高(百万ドル) 13.68300
企業価値(EV) 企業価値(EV)(百万ドル) 225.60820
当期純利益 当期純利益(百万ドル) -85.45400
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 Strongbridge Biopharma plc revenues increased from $1.5M to $8.2M. Net loss decreased 47% to $31.6M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Lower net loss reflects Research and development decrease from $7.1M (expense) to $398.1M (income) Unrealized gain on fair value of warrant increase from $30.1M (expense) to $9.3M (income).

 SBBPのテクニカル分析


 SBBPのニュース

   Xeris Pharmaceuticals Completes Acquisition of Strongbridge Biopharma  2021/10/05 20:05:00 Business Wire
CHICAGO--(BUSINESS WIRE)--Xeris Pharmaceuticals, Inc. (Xeris), a pharmaceutical company leveraging its novel formulation technology platforms to develop and commercialize ready-to-use injectable drug formulations, today announced that it has successfully completed the previously announced acquisition of Strongbridge Biopharma plc (Nasdaq: SBBP) (Strongbridge). Under the terms of the acquisition agreement, the businesses of Xeris and Strongbridge are now combined under Xeris Biopharma Holdin
   What Market views are telling to dormant Investors? Delta Air Lines, Inc. (NYSE:DAL 2.21%), Strongbridge Biopharma plc (NASDAQ:SBBP -1.88%)  2021/09/26 23:48:19 Stock Equity
There are two main reasons why moving averages are useful in forex trading: moving averages help traders define trend recognize changes in trend. Now well have a look on, SMA50 The post What Market views are telling to dormant Investors? Delta Air Lines, Inc. (NYSE:DAL 2.21%), Strongbridge Biopharma plc (NASDAQ:SBBP -1.88%) appeared first on Stocks Equity .
   Strongbridge Biopharma plc Announces Court Hearing Date to Approve Proposed Acquisition by Xeris Pharmaceuticals, Inc.  2021/09/23 20:01:00 Intrado Digital Media
DUBLIN, Ireland and TREVOSE, Pa., Sept. 23, 2021 (GLOBE NEWSWIRE) -- Strongbridge Biopharma plc (NASDAQ: SBBP) (the Company or Strongbridge ) today announced that the High Court of Ireland (the Court ) has set the date of the final court hearing to sanction the proposed acquisition of Strongbridge by Xeris Pharmaceuticals, Inc. ( Xeris ) by means of scheme of arrangement (the Scheme ) under Chapter 1 of Part 9 of the Irish Companies Act 2014 (the Act ).
   Dynamic volume-return relation of individual stocks: The Coca-Cola Company (NYSE:KO -1.64%), Strongbridge Biopharma plc (NASDAQ:SBBP 1.44%)  2021/09/20 00:10:28 Stock Equity
There are two main reasons why moving averages are useful in forex trading: moving averages help traders define trend recognize changes in trend. Now well have a look on, SMA50 The post Dynamic volume-return relation of individual stocks: The Coca-Cola Company (NYSE:KO -1.64%), Strongbridge Biopharma plc (NASDAQ:SBBP 1.44%) appeared first on Stocks Equity .
   Xeris'' rises 5% as stockholders approve Strongbridge Biopharma acquisition  2021/09/14 20:28:30 Seeking Alpha
   Xeris Pharmaceuticals Completes Acquisition of Strongbridge Biopharma  2021/10/05 20:05:00 Business Wire
CHICAGO--(BUSINESS WIRE)--Xeris Pharmaceuticals, Inc. (Xeris), a pharmaceutical company leveraging its novel formulation technology platforms to develop and commercialize ready-to-use injectable drug formulations, today announced that it has successfully completed the previously announced acquisition of Strongbridge Biopharma plc (Nasdaq: SBBP) (Strongbridge). Under the terms of the acquisition agreement, the businesses of Xeris and Strongbridge are now combined under Xeris Biopharma Holdin
   What Market views are telling to dormant Investors? Delta Air Lines, Inc. (NYSE:DAL 2.21%), Strongbridge Biopharma plc (NASDAQ:SBBP -1.88%)  2021/09/26 23:48:19 Stock Equity
There are two main reasons why moving averages are useful in forex trading: moving averages help traders define trend recognize changes in trend. Now well have a look on, SMA50 The post What Market views are telling to dormant Investors? Delta Air Lines, Inc. (NYSE:DAL 2.21%), Strongbridge Biopharma plc (NASDAQ:SBBP -1.88%) appeared first on Stocks Equity .
   Strongbridge Biopharma plc Announces Court Hearing Date to Approve Proposed Acquisition by Xeris Pharmaceuticals, Inc.  2021/09/23 20:01:00 Intrado Digital Media
DUBLIN, Ireland and TREVOSE, Pa., Sept. 23, 2021 (GLOBE NEWSWIRE) -- Strongbridge Biopharma plc (NASDAQ: SBBP) (the Company or Strongbridge ) today announced that the High Court of Ireland (the Court ) has set the date of the final court hearing to sanction the proposed acquisition of Strongbridge by Xeris Pharmaceuticals, Inc. ( Xeris ) by means of scheme of arrangement (the Scheme ) under Chapter 1 of Part 9 of the Irish Companies Act 2014 (the Act ).
   Dynamic volume-return relation of individual stocks: The Coca-Cola Company (NYSE:KO -1.64%), Strongbridge Biopharma plc (NASDAQ:SBBP 1.44%)  2021/09/20 00:10:28 Stock Equity
There are two main reasons why moving averages are useful in forex trading: moving averages help traders define trend recognize changes in trend. Now well have a look on, SMA50 The post Dynamic volume-return relation of individual stocks: The Coca-Cola Company (NYSE:KO -1.64%), Strongbridge Biopharma plc (NASDAQ:SBBP 1.44%) appeared first on Stocks Equity .
   Xeris'' rises 5% as stockholders approve Strongbridge Biopharma acquisition  2021/09/14 20:28:30 Seeking Alpha
   Somatostatin Receptor Type 4 (SSTR4) Drugs In Development, 2021 Research Report Featuring Eli Lilly and Co, GlyTech, Peptide Logic, Strongbridge Biopharma - ResearchAndMarkets.com  2021/07/20 08:26:00 Business Wire
DUBLIN--(BUSINESS WIRE)--The "Somatostatin Receptor Type 4 (SSTR4) - Drugs In Development, 2021" drug pipelines has been added to ResearchAndMarkets.com''s offering. Somatostatin Receptor Type 4 (SSTR4) pipeline Target constitutes close to 5 molecules. The latest report Somatostatin Receptor Type 4 - Drugs In Development, 2021, outlays comprehensive information on the Somatostatin Receptor Type 4 (SSTR4) targeted therapeutics, complete with analysis by indications, stage of development, mechanis
   Avenue 1 Advisors, LLC Buys Roper Technologies Inc, Strongbridge Biopharma PLC, iShares S&P ...  2021/07/14 22:38:19 GuruFocus
Related Stocks: IVW , ROP , SBBP , HIG , INTC ,
   Strongbridge Biopharma plc Announces Publication of Long-term Efficacy and Safety Results for KEVEYIS® (dichlorphenamide) for the Treatment of Primary Periodic Paralysis in Muscle & Nerve  2021/07/13 11:30:00 Intrado Digital Media
~ Study Confirms Long-Term Treatment with KEVEYIS is Safe and Effective for Chronic Use ~
   Tudor Capital Europe LLP - Form 8.3 - Strongbridge Biopharma Plc  2021/06/28 12:16:00 FinanzNachrichten
Tudor Capital Europe LLP - Form 8.3 - Strongbridge Biopharma Plc PR Newswire London, June 28 Ap19 FORM 8.3 IRISH TAKEOVER PANEL DISCLOSURE UNDER RULE 8.3 OF THE IRISH TAKEOVER PANEL ACT, 1997, TAK
   Strongbridge Biopharma plc (NASDAQ: SBBP): How Can A Stock Be Up 22.63% Year To Date, But Still Loser  2021/06/25 11:01:00 Investor Newsletter
Strongbridge Biopharma plc (NASDAQ:SBBP)s traded shares stood at 0.56 million during the latest session, with the companys beta value hitting 1.58. At the last check today, the stocks price was $2.99, to imply an increase of 0.50% or $0.01 in intraday trading. The SBBP shares 52-week high remains $4.40, putting it -47.16% down since that []

 関連キーワード  (医薬品 米国株 ストロングブリッジ・バイオファ―マ SBBP Strongbridge Biopharma plc)

 twitter  (公式ツイッターやCEOツイッターなど)